TGTX · TG Therapeutics, Inc.

Current Thesis

TG Therapeutics’ recovery rests on BRIUMVI sales growth sustaining the commercial story; confirmation requires a weekly close above the $59.06 reference high and further revenue growth at the next quarterly report, while a weekly close below $46 breaks the structure. The 2026-09-11 adjusted close was $53.89, 8.8% below the supplied 52-week high. The 2026-08-03 results established the operating benchmark: second-quarter US BRIUMVI net revenue of $227.7 million and full-year US guidance of $890–905 million.

The inference is that the narrative is maturing — the 2026-09-11 close remains near the 2026-08-28 close of $53.93 after the acquisition-rumour coverage clustered on 2026-08-21. At the 2026-09-09 Cantor conference, chief executive Michael Weiss said there was no update to the quarterly guidance discussion. That supports continuity of management’s outlook, without establishing another revenue acceleration. Cantor conference transcript.

The earlier absence of a near-term company event has changed: a 2026-09-10 announcement schedules a management fireside chat for 2026-09-14. The announcement promises a discussion, with no specified clinical release. Company announcement.

Bullish and bearish views on TG Therapeutics, Inc.

The model's bull view on TG Therapeutics, Inc. (TGTX), in brief: Commercial growth remains measurable. The 2026-08-03 results reported second-quarter US BRIUMVI net revenue of $227.7 million, up approximately 64% year over year, alongside approximately $950 million of full-year global revenue guidance. These are the operating anchors for the… The bear view: Revenue growth has spending demands. The 2026-08-03 release reported second-quarter earnings per share of $0.05 and research and development expense of $95.3 million, including approximately $54.6 million of subcutaneous manufacturing costs. Revenue growth alone therefore does… Both cases follow in full.

Bull Case

• Commercial growth remains measurable. The 2026-08-03 results reported second-quarter US BRIUMVI net revenue of $227.7 million, up approximately 64% year over year, alongside approximately $950 million of full-year global revenue guidance. These are the operating anchors for the recovery thesis.
• Dosing development has clinical evidence. The company’s 2026-05-27 ENHANCE announcement reported that the consolidated initial infusion met its exposure-equivalence endpoint. That supports the proposed dosing simplification; it does not establish approval.
• Analyst support has a date. H.C. Wainwright maintained its $78 price target on 2026-09-01, according to the supplied rating report. That is the analyst’s valuation view, separate from the market’s $53.89 close on 2026-09-11.

Bear Case

• Revenue growth has spending demands. The 2026-08-03 release reported second-quarter earnings per share of $0.05 and research and development expense of $95.3 million, including approximately $54.6 million of subcutaneous manufacturing costs. Revenue growth alone therefore does not establish improving earnings conversion.
• Acquisition attention lacks transaction evidence. The 2026-08-21 Betaville alert was explicitly unverified, and the coverage supplied no named buyer or company confirmation. It cannot establish an acquisition outcome.
• Expansion evidence remains preliminary. The 2026-06-09 myasthenia gravis announcement concerned an open-label Phase 1 study with 11 participants. The sample is too small to support a claim of efficacy in a broader patient population.

Setup & Price Structure

The 2026-09-11 adjusted series records a $53.89 close, a three-month price gain of 8.8%, and a 14-period relative strength index (RSI) of 48.5. The same snapshot places the stock 8.8% below its $59.06 52-week high. No moving-average value or volume series is supplied, so neither distance above a rising average nor expanding participation is established.

The $46–48 market shelf identified in the 2026-08-30 research remains the structural reference. A weekly close below $46 would invalidate the recovery thesis; a weekly close above the $59.06 high identified in the 2026-09-11 snapshot would satisfy its price-confirmation condition. The current snapshot alone cannot establish the intervening daily path.

Crowding evidence is dated rather than current: Barchart, GuruFocus, Stocktwits and Seeking Alpha coverage clustered around the 2026-08-21 rumour. The available short-interest observation is approximately 30 million shares at the 2026-06-15 settlement, attributed to FINRA data through shortinteresthistory.com. That observation cannot establish September positioning. The 2026-08-31 settlement report was scheduled for publication on 2026-09-10, but its TGTX figure is missing here. FINRA reporting calendar.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Short-interest publication. FINRA schedules publication for the 2026-09-15 settlement. This supplies a dated test of whether the historical short-interest figure remains representative. FINRA reporting calendar.
• 2026-10-09 — Short-interest publication. FINRA schedules publication for the 2026-09-30 settlement. The release can extend the positioning record, although a short sequence cannot establish a persistent trend. FINRA reporting calendar.
• ~2026-11-03, est. Third-quarter results. This remains an unconfirmed date from the 2026-08-30 coverage. The commercial test is US BRIUMVI net revenue above the second quarter’s $227.7 million while maintaining or increasing the $890–905 million full-year US guidance issued on 2026-08-03.

Elapsed catalysts

• 2026-09-14 — H.C. Wainwright conference discussion. The company’s 2026-09-10 announcement schedules the fireside chat for noon Eastern Time. Any explicit revision to commercial guidance or clinical timing would change the evidence; attendance alone does not confirm the thesis. Company announcement. (passed 6d ago)

What Would Change Our Mind

Loss of the June breakout-retest shelf identified in the 2026-08-30 coverage would end the structural recovery case: a weekly close below $46 is the published price invalidation. Separately, third-quarter US BRIUMVI net revenue below the $227.7 million second-quarter benchmark, or a reduction to the $890–905 million full-year US guidance, would invalidate the commercial-growth premise.

The positive case requires both a weekly close above the $59.06 reference high in the 2026-09-11 snapshot and the quarterly revenue confirmation specified above. The scheduled 2026-09-14 conference does not substitute for either condition.

Correlation Notes

This is a single-name commercial and clinical setup. The 2026-08-03 earnings reaction and the 2026-08-21 acquisition-rumour session are company-specific observations; that sample is too small to support a sector-correlation claim. No paired sector-return series is available for the 2026-09-11 price snapshot, so a numerical correlation or diversification claim is unsupported.